A Prospective Study on 18 F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer
F-DCFPyL (2-(3-{1-carboxy-5-[(6- F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of...
Gespeichert in:
| Veröffentlicht in: | Journal of Nuclear Medicine 2019-11, Vol.60 (11), p.1587-1593 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1593 |
|---|---|
| container_issue | 11 |
| container_start_page | 1587 |
| container_title | Journal of Nuclear Medicine |
| container_volume | 60 |
| creator | Rousseau, Etienne Wilson, Don Lacroix-Poisson, Frédéric Krauze, Andra Chi, Kim Gleave, Martin McKenzie, Michael Tyldesley, Scott Goldenberg, S Larry Bénard, François |
| description | F-DCFPyL (2-(3-{1-carboxy-5-[(6-
F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of
F-DCFPyL in the setting of biochemical recurrence of prostate cancer.
Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. The subjects underwent
F-DCFPyL PET/CT imaging. The localization and number of lesions were recorded. The uptake characteristics of the 5 most active lesions were measured. A pre- and posttest questionnaire was sent to treating physicians to assess the impact on management.
One hundred thirty subjects were evaluated.
F-DCFPyL PET/CT localized recurrent prostate cancer in 60% of cases with a prostate-specific antigen (PSA) level of ≥0.4 to |
| doi_str_mv | 10.2967/jnumed.119.226381 |
| format | Article |
| fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2967_jnumed_119_226381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>30979820</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1130-95aa511433d55a72fd36a31214b57e71e7269343aa591ec4d7edfeb1d2dabde13</originalsourceid><addsrcrecordid>eNo1kN1OwkAQRjdGI4g-gDdmX6BlZ7e7215iBSXBSASvm-3uFEtoS_pjwttbrFxNMvOdb5JDyCMwn0dKT_dlV6DzASKfcyVCuCJjkEJ6Uil9TcYMFHhSMjkid02zZ4ypMAxvyUiwSEchZ2NiZ3RdV80RbZv_IN20nTvRqqQQ0oX3Ei_WpxVdb9771Hw7jbd0WZhdXu5oXtLnvLLfWOTWHOgn2q6usbRIq-yvsTUt0tj0m_qe3GTm0ODD_5yQr8V8G795q4_XZTxbeRZAMC-SxkiAQAgnpdE8c0IZARyCVGrUgJqrSASiT0WANnAaXYYpOO5M6hDEhMDQa_v_TY1ZcqzzwtSnBFhyFpYMwpJeWDII65mngTl26fl0IS6GxC9-N2ZN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>A Prospective Study on 18 F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Rousseau, Etienne ; Wilson, Don ; Lacroix-Poisson, Frédéric ; Krauze, Andra ; Chi, Kim ; Gleave, Martin ; McKenzie, Michael ; Tyldesley, Scott ; Goldenberg, S Larry ; Bénard, François</creator><creatorcontrib>Rousseau, Etienne ; Wilson, Don ; Lacroix-Poisson, Frédéric ; Krauze, Andra ; Chi, Kim ; Gleave, Martin ; McKenzie, Michael ; Tyldesley, Scott ; Goldenberg, S Larry ; Bénard, François</creatorcontrib><description>F-DCFPyL (2-(3-{1-carboxy-5-[(6-
F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of
F-DCFPyL in the setting of biochemical recurrence of prostate cancer.
Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. The subjects underwent
F-DCFPyL PET/CT imaging. The localization and number of lesions were recorded. The uptake characteristics of the 5 most active lesions were measured. A pre- and posttest questionnaire was sent to treating physicians to assess the impact on management.
One hundred thirty subjects were evaluated.
F-DCFPyL PET/CT localized recurrent prostate cancer in 60% of cases with a prostate-specific antigen (PSA) level of ≥0.4 to <0.5, 78% with a level of ≥0.5 to <1.0, 72% with a level of ≥1.0 to <2.0, and 92% with a level of ≥2.0. Many subjects had few lesions (1 lesion in 40.8%, 2 in 8.5%, and 3 in 4.6%). The number of lesions was significantly related to PSA by ANOVA, but there was a large overlap in the PSA values for number of lesion categories. Total lesion uptake was also significantly related to PSA level. A change in treatment intent occurred in 65.5% of subjects, disease stage changed in 65.5%, and management plans changed in 87.3%. Twenty-two subjects reported mild adverse events after the scan; all resolved completely.
F-DCFPyL PET/CT is safe and sensitive for the localization of biochemical recurrence of prostate cancer. This test improved decision making for referring oncologists and changed management for most subjects.</description><identifier>ISSN: 0161-5505</identifier><identifier>EISSN: 1535-5667</identifier><identifier>EISSN: 2159-662X</identifier><identifier>DOI: 10.2967/jnumed.119.226381</identifier><identifier>PMID: 30979820</identifier><language>eng</language><publisher>United States</publisher><subject>Aged ; Antigens, Surface - chemistry ; Glutamate Carboxypeptidase II - chemistry ; Humans ; Lysine - analogs & derivatives ; Lysine - chemistry ; Male ; Positron Emission Tomography Computed Tomography ; Prospective Studies ; Prostatic Neoplasms - diagnostic imaging ; Prostatic Neoplasms - metabolism ; Recurrence ; Urea - analogs & derivatives ; Urea - chemistry</subject><ispartof>Journal of Nuclear Medicine, 2019-11, Vol.60 (11), p.1587-1593</ispartof><rights>2019 by the Society of Nuclear Medicine and Molecular Imaging.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1130-95aa511433d55a72fd36a31214b57e71e7269343aa591ec4d7edfeb1d2dabde13</citedby><cites>FETCH-LOGICAL-c1130-95aa511433d55a72fd36a31214b57e71e7269343aa591ec4d7edfeb1d2dabde13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30979820$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rousseau, Etienne</creatorcontrib><creatorcontrib>Wilson, Don</creatorcontrib><creatorcontrib>Lacroix-Poisson, Frédéric</creatorcontrib><creatorcontrib>Krauze, Andra</creatorcontrib><creatorcontrib>Chi, Kim</creatorcontrib><creatorcontrib>Gleave, Martin</creatorcontrib><creatorcontrib>McKenzie, Michael</creatorcontrib><creatorcontrib>Tyldesley, Scott</creatorcontrib><creatorcontrib>Goldenberg, S Larry</creatorcontrib><creatorcontrib>Bénard, François</creatorcontrib><title>A Prospective Study on 18 F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer</title><title>Journal of Nuclear Medicine</title><addtitle>J Nucl Med</addtitle><description>F-DCFPyL (2-(3-{1-carboxy-5-[(6-
F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of
F-DCFPyL in the setting of biochemical recurrence of prostate cancer.
Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. The subjects underwent
F-DCFPyL PET/CT imaging. The localization and number of lesions were recorded. The uptake characteristics of the 5 most active lesions were measured. A pre- and posttest questionnaire was sent to treating physicians to assess the impact on management.
One hundred thirty subjects were evaluated.
F-DCFPyL PET/CT localized recurrent prostate cancer in 60% of cases with a prostate-specific antigen (PSA) level of ≥0.4 to <0.5, 78% with a level of ≥0.5 to <1.0, 72% with a level of ≥1.0 to <2.0, and 92% with a level of ≥2.0. Many subjects had few lesions (1 lesion in 40.8%, 2 in 8.5%, and 3 in 4.6%). The number of lesions was significantly related to PSA by ANOVA, but there was a large overlap in the PSA values for number of lesion categories. Total lesion uptake was also significantly related to PSA level. A change in treatment intent occurred in 65.5% of subjects, disease stage changed in 65.5%, and management plans changed in 87.3%. Twenty-two subjects reported mild adverse events after the scan; all resolved completely.
F-DCFPyL PET/CT is safe and sensitive for the localization of biochemical recurrence of prostate cancer. This test improved decision making for referring oncologists and changed management for most subjects.</description><subject>Aged</subject><subject>Antigens, Surface - chemistry</subject><subject>Glutamate Carboxypeptidase II - chemistry</subject><subject>Humans</subject><subject>Lysine - analogs & derivatives</subject><subject>Lysine - chemistry</subject><subject>Male</subject><subject>Positron Emission Tomography Computed Tomography</subject><subject>Prospective Studies</subject><subject>Prostatic Neoplasms - diagnostic imaging</subject><subject>Prostatic Neoplasms - metabolism</subject><subject>Recurrence</subject><subject>Urea - analogs & derivatives</subject><subject>Urea - chemistry</subject><issn>0161-5505</issn><issn>1535-5667</issn><issn>2159-662X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kN1OwkAQRjdGI4g-gDdmX6BlZ7e7215iBSXBSASvm-3uFEtoS_pjwttbrFxNMvOdb5JDyCMwn0dKT_dlV6DzASKfcyVCuCJjkEJ6Uil9TcYMFHhSMjkid02zZ4ypMAxvyUiwSEchZ2NiZ3RdV80RbZv_IN20nTvRqqQQ0oX3Ei_WpxVdb9771Hw7jbd0WZhdXu5oXtLnvLLfWOTWHOgn2q6usbRIq-yvsTUt0tj0m_qe3GTm0ODD_5yQr8V8G795q4_XZTxbeRZAMC-SxkiAQAgnpdE8c0IZARyCVGrUgJqrSASiT0WANnAaXYYpOO5M6hDEhMDQa_v_TY1ZcqzzwtSnBFhyFpYMwpJeWDII65mngTl26fl0IS6GxC9-N2ZN</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Rousseau, Etienne</creator><creator>Wilson, Don</creator><creator>Lacroix-Poisson, Frédéric</creator><creator>Krauze, Andra</creator><creator>Chi, Kim</creator><creator>Gleave, Martin</creator><creator>McKenzie, Michael</creator><creator>Tyldesley, Scott</creator><creator>Goldenberg, S Larry</creator><creator>Bénard, François</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>201911</creationdate><title>A Prospective Study on 18 F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer</title><author>Rousseau, Etienne ; Wilson, Don ; Lacroix-Poisson, Frédéric ; Krauze, Andra ; Chi, Kim ; Gleave, Martin ; McKenzie, Michael ; Tyldesley, Scott ; Goldenberg, S Larry ; Bénard, François</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1130-95aa511433d55a72fd36a31214b57e71e7269343aa591ec4d7edfeb1d2dabde13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Aged</topic><topic>Antigens, Surface - chemistry</topic><topic>Glutamate Carboxypeptidase II - chemistry</topic><topic>Humans</topic><topic>Lysine - analogs & derivatives</topic><topic>Lysine - chemistry</topic><topic>Male</topic><topic>Positron Emission Tomography Computed Tomography</topic><topic>Prospective Studies</topic><topic>Prostatic Neoplasms - diagnostic imaging</topic><topic>Prostatic Neoplasms - metabolism</topic><topic>Recurrence</topic><topic>Urea - analogs & derivatives</topic><topic>Urea - chemistry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rousseau, Etienne</creatorcontrib><creatorcontrib>Wilson, Don</creatorcontrib><creatorcontrib>Lacroix-Poisson, Frédéric</creatorcontrib><creatorcontrib>Krauze, Andra</creatorcontrib><creatorcontrib>Chi, Kim</creatorcontrib><creatorcontrib>Gleave, Martin</creatorcontrib><creatorcontrib>McKenzie, Michael</creatorcontrib><creatorcontrib>Tyldesley, Scott</creatorcontrib><creatorcontrib>Goldenberg, S Larry</creatorcontrib><creatorcontrib>Bénard, François</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Journal of Nuclear Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rousseau, Etienne</au><au>Wilson, Don</au><au>Lacroix-Poisson, Frédéric</au><au>Krauze, Andra</au><au>Chi, Kim</au><au>Gleave, Martin</au><au>McKenzie, Michael</au><au>Tyldesley, Scott</au><au>Goldenberg, S Larry</au><au>Bénard, François</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Prospective Study on 18 F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer</atitle><jtitle>Journal of Nuclear Medicine</jtitle><addtitle>J Nucl Med</addtitle><date>2019-11</date><risdate>2019</risdate><volume>60</volume><issue>11</issue><spage>1587</spage><epage>1593</epage><pages>1587-1593</pages><issn>0161-5505</issn><eissn>1535-5667</eissn><eissn>2159-662X</eissn><abstract>F-DCFPyL (2-(3-{1-carboxy-5-[(6-
F-fluoro-pyridine-3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid), a prostate-specific membrane antigen-targeting radiotracer, has shown promise as a prostate cancer imaging radiotracer. We evaluated the safety, sensitivity, and impact on patient management of
F-DCFPyL in the setting of biochemical recurrence of prostate cancer.
Subjects with prostate cancer and biochemical recurrence after radical prostatectomy or curative-intent radiotherapy were included in this prospective study. The subjects underwent
F-DCFPyL PET/CT imaging. The localization and number of lesions were recorded. The uptake characteristics of the 5 most active lesions were measured. A pre- and posttest questionnaire was sent to treating physicians to assess the impact on management.
One hundred thirty subjects were evaluated.
F-DCFPyL PET/CT localized recurrent prostate cancer in 60% of cases with a prostate-specific antigen (PSA) level of ≥0.4 to <0.5, 78% with a level of ≥0.5 to <1.0, 72% with a level of ≥1.0 to <2.0, and 92% with a level of ≥2.0. Many subjects had few lesions (1 lesion in 40.8%, 2 in 8.5%, and 3 in 4.6%). The number of lesions was significantly related to PSA by ANOVA, but there was a large overlap in the PSA values for number of lesion categories. Total lesion uptake was also significantly related to PSA level. A change in treatment intent occurred in 65.5% of subjects, disease stage changed in 65.5%, and management plans changed in 87.3%. Twenty-two subjects reported mild adverse events after the scan; all resolved completely.
F-DCFPyL PET/CT is safe and sensitive for the localization of biochemical recurrence of prostate cancer. This test improved decision making for referring oncologists and changed management for most subjects.</abstract><cop>United States</cop><pmid>30979820</pmid><doi>10.2967/jnumed.119.226381</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0161-5505 |
| ispartof | Journal of Nuclear Medicine, 2019-11, Vol.60 (11), p.1587-1593 |
| issn | 0161-5505 1535-5667 2159-662X |
| language | eng |
| recordid | cdi_crossref_primary_10_2967_jnumed_119_226381 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Aged Antigens, Surface - chemistry Glutamate Carboxypeptidase II - chemistry Humans Lysine - analogs & derivatives Lysine - chemistry Male Positron Emission Tomography Computed Tomography Prospective Studies Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - metabolism Recurrence Urea - analogs & derivatives Urea - chemistry |
| title | A Prospective Study on 18 F-DCFPyL PSMA PET/CT Imaging in Biochemical Recurrence of Prostate Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T02%3A06%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Prospective%20Study%20on%2018%20F-DCFPyL%20PSMA%20PET/CT%20Imaging%20in%20Biochemical%20Recurrence%20of%20Prostate%20Cancer&rft.jtitle=Journal%20of%20Nuclear%20Medicine&rft.au=Rousseau,%20Etienne&rft.date=2019-11&rft.volume=60&rft.issue=11&rft.spage=1587&rft.epage=1593&rft.pages=1587-1593&rft.issn=0161-5505&rft.eissn=1535-5667&rft_id=info:doi/10.2967/jnumed.119.226381&rft_dat=%3Cpubmed_cross%3E30979820%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/30979820&rfr_iscdi=true |